TGF-β signalling-related markers in cancer patients with bone metastasis

References

• Akhurst RJ, Derynck R. TGF-beta signaling in cancer – a double-edged sword. Trends in Cell Biology 2001; 11: S44–S51
   PubMed Web of Science ®Google Scholar
• Akhurst RJ, Fee F, Balmain A. Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. Nature 1988; 331: 363–365
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun LZ. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-{beta} type I receptor kinase inhibitor. Cancer Research 2006; 66: 6714–6721
   PubMed Web of Science ®Google Scholar
• Barthelemy-Brichant N, David JL, Bosquee L, Bury T, Seidel L, Albert A, Bartsch P, Baugnet-Mahieu L, Deneufbourg JM. Increased TGFbeta1 plasma level in patients with lung cancer: potential mechanisms. European Journal of Clinical Investigation 2002; 32: 193–198
   PubMed Web of Science ®Google Scholar
• Benjamani Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple tasting. Journal of the Royal Statistical Society B 1995; 57: 289–300
   Google Scholar
• Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Research 2004; 64: 252–261
   PubMed Web of Science ®Google Scholar
• Buyukasik Y, Soylu B, Soylu AR, Ozcebe OI, Canbakan S, Haznedaroglu IC, Kirazli S, Baser Y, Dundar SV. In vivo platelet and T-lymphocyte activities during pulmonary tuberculosis. European Respiratory Journal 1998; 12: 1375–1379
   PubMed Web of Science ®Google Scholar
• Caine G, Stonelakey P, Lip G, Kehoe S. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4: 465–473
   PubMed Web of Science ®Google Scholar
• Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-beta. Breast Cancer Research 2000; 2: 125–132
   PubMed Web of Science ®Google Scholar
• Farrington DL, Yingling JM, Fill JA, Yan L, Qian Y-W, Shou J, Wang X, Ehsani ME, Cleverly AL, Daly TM, Lahn M, Konrad RJ, Ray CJ. Development and validation of a phosphorylated SMAD ex vivo stimulation assay. Biomarkers 2007; 12: 313–330
   PubMed Web of Science ®Google Scholar
• Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002; 7: 401–409
   PubMed Web of Science ®Google Scholar
• Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, Herbst RS, Carducci M, Britten CD, Basche M, Eckhardt SG, Thornton D. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clinical Cancer Research 2006; 12: 3408–3415
   PubMed Web of Science ®Google Scholar
• Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. Journal of Immunology 2006; 177: 896–904
   PubMed Web of Science ®Google Scholar
• Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. Journal of Biological Chemistry 2002; 277: 24571–2478
   PubMed Web of Science ®Google Scholar
• Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proceedings of the National Academy of Sciences USA 2001; 98: 3018–3023
   PubMed Web of Science ®Google Scholar
• Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proceedings of the National Academy of Sciences USA 2005; 102: 13909–13914
   PubMed Web of Science ®Google Scholar
• Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537–549
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Kowal K, Lewszuk A, Bodzenta-Lukaszyk A, Walecki J, Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Annals of the Rheumatic Diseases 2005; 64: 484–486
   PubMed Web of Science ®Google Scholar
• Lahn M, Kloeker S, Berry BS. TGF-beta inhibitors for the treatment of cancer. Expert Opinions on Investigational Drugs 2005; 14: 629–643
   PubMed Web of Science ®Google Scholar
• Levine SP, Lindenfeld J, Ellis JB, Raymond NM, Krentz LS. Increased plasma concentrations of platelet factor 4 in coronary artery disease: a measure of in vivo platelet activation and secretion. Circulation 1981; 64: 626–632
   PubMed Web of Science ®Google Scholar
• Li Z-G, Yingling JM, Logothetis C, Navone NM. 2006. TGF1 receptor kinase inhibitor inhibits prostate cancer growth in bone. In: Res PAAC AACR Annual Meeting 2006. Washington, DC: American Association for Cancer Research. Abstract No. 2922.
   Google Scholar
• Matsushita T, Dong Z, Sadler J. von Willebrand's factor and von Willebrand's disease. Current Opinion on Hematology 1994; 1: 362–368
   PubMedGoogle Scholar
• O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clinical Cancer Research 2003; 9: 5465–5476
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Thiebaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Ruckert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thurlimann B, Clemens MR, Eghbali H, Body JJ. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. Journal of Clinical Endocrinology & Metabolism 1999; 84: 3545–3550
   PubMed Web of Science ®Google Scholar
• Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proceedings of the National Academy of Sciences USA 1981; 78: 5339–5343
   PubMed Web of Science ®Google Scholar
• Rohsig LM, Damin DC, Stefani SD, Castro CG, Jr, Roisenberg I, Schwartsmann G. von Willebrand factor antigen levels in plasma of patients with malignant breast disease. Brazilian Journal of Medical & Biological Research 2001; 34: 1125–1129
   PubMed Web of Science ®Google Scholar
• Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nature Reviews Cancer 2003; 3: 807–821
   PubMed Web of Science ®Google Scholar
• Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences USA 2003; 100: 8430–8435
   PubMed Web of Science ®Google Scholar
• Slungaard A. Platelet factor 4 modulation of the thrombomodulin-protein C system. Critical Care Medicine 2004; 32: S331–S335
   Web of Science ®Google Scholar
• Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985; 313: 745–747
   PubMed Web of Science ®Google Scholar
• Vincent-Salomon A, Carton M, Zafrani B, Freneaux P, Nicolas A, Massemin B, Fourquet A, Clough K, Pouillart P, Sastre-Garau X. Long term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases. Cancer 2001; 92: 249–256
   PubMed Web of Science ®Google Scholar
• Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Current Opinions on Genetic Development 2002; 12: 22–29
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. Journal of Immunotherapy 1997; 20: 165–177
   PubMed Web of Science ®Google Scholar
• Wynendaele W, Derua R, Hoylaerts MF, Pawinski A, Waelkens E, de Bruijn EA, Paridaens R, Merlevede W, van Oosterom AT. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?. Annals of Oncology 1999; 10: 965–971
   PubMed Web of Science ®Google Scholar
• Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. Journal of Clinical Investigations 1999; 103: 197–206
   PubMed Web of Science ®Google Scholar
• Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nature Reviews Drug Discovery 2004; 3: 1011–1022
   PubMed Web of Science ®Google Scholar
• Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomarkers 2005; 1: 259–269
   PubMedGoogle Scholar